Agitation clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

    open to eligible people ages 50-90

    This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

    Los Angeles 5368361, California 5332921 and other locations

Our lead scientists for Agitation research studies include .

Last updated: